
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
Hou J et al. N Engl J Med 2024;391:2098-2109, DOI: 10.1056/NEJMoa2405485 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Hou J et al. N Engl J Med 2024;391:2098-2109, DOI: 10.1056/NEJMoa2405485 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Dongelmans EJ, Hirode G, Hansen BE, Chen CH, Su TH, Seto WK, Furquim d’Almeida A, van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff

Grebely J, Matthews S, Causer LM, Feld JJ, Cunningham P, Dore GJ, Applegate TL. We have reached single-visit testing, diagnosis, and treatment for hepatitis C

Pol S, Thompson A, Collins M, Venier E, Cotte L, Laguno Centeno M, et al. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the

Grishma H, Bettina H, Chien-Hung C et al, on behalf of the RETRACT-B study group. Am J Gastroenterol, 2024 DOI: 10.14309/ajg.0000000000002759 Πατώντας ΕΔΩ μπορείτε να

Wang B, Zhou J, Wu X, Sun Y, Li L, Li P, et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression:

Semmler G, Alonso lópez S, Pons M, Lens S, Dajti E, Griemsmann M, et al. Published: March 21, 2024, Journal of Hepatology DOI: https://doi.org/10.1016/j.jhep.2024.03.015 Πατώντας

Lee MH, Chen YT, Huang YH, Yang HI, Chen HY, Chen CJ, et al Published: February 16, 2024 DOI:https://doi.org/10.1016/j.cgh.2024.01.045 Πατώντας ΕΔΩ μπορείτε να δείτε την

Zhang Y, Liu X, Li S, Lin C, Ye Q, Wang Y, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation:

Lu M, Salgia R, Li J, et al. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2023;30:746–755. DOI: